RLD2001-1

RLD2001-1 is an orally administered small molecule drug developed by Hanmi Pharmaceutical for the treatment of essential hypertension. It has reached Phase 3 clinical trials, primarily targeting patients with essential hypertension who are inadequately controlled on monotherapy. The drug is being evaluated in randomized, double-blind, active-controlled studies comparing its efficacy and safety to other antihypertensive agents. While some sources mention a potential focus on advanced-stage solid tumors resistant to standard therapies, the most consistent and well-supported indication is essential hypertension[2][3][4][9]. The precise mechanism of action and molecular target have not been publicly disclosed.